Study S002532

A Phase 1 Randomized, Double-blind, Placebo-controlled Single-ascending Dose and Multiple-ascending Dose (SAD and MAD) Trial to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Novel Glucagon-like Peptide-1 Receptor Agonist (GLP-1RA) BLX-7006 in Healthy Adults With a Body Mass Index (BMI) of 20 - 35 kg/m2

ClinicalTrials.gov record

Registration

Registration: NCT07140055
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: TRIPLE
Status: NOT_YET_RECRUITING
Enrollment: 76
Start: 2025-09
Primary completion: 2026-04
Lead sponsor: Biolexis Therapeutics
Conditions: Normal Healthy Volunteer; Safety After Oral Intake
Interventions: DRUG:BLX-7006; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Number of participants who experienced Adverse Events (AEs) [From first dose through End of Study (up to ~28 days per participant)]
Number of participants who experienced Serious Adverse Events (SAEs) [From first dose through End of Study (up to ~28 days per participant)]
Number of participants who experienced Treatment-Related Adverse Avents (TRAEs) [From first dose through End of Study (up to ~28 days per participant)]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.